1 and specific mRNA, of the cDNA encoding this platelet inhibitor.

2  the well appreciated action of aspirin as a platelet inhibitor.

3 years (SD 9), 85% were male, 92% were taking platelet inhibitors, 62% beta blockers, and 58% lipid-lo

4 Arginine-glycine-aspartic acid (RGD)-mimetic platelet inhibitors act by occupying the RGD recognition

5 d platelet agonist; prostacyclin is a potent platelet inhibitor and vasodilator.

6 requently prescribed aspirin, beta-blockers, platelet inhibitors, and statins (all p < 0.0001).

7                                              Platelet inhibitors are the mainstay of drug therapy to

8       These represent intriguing targets for platelet inhibitor development or shed light on the over

9 d the ability of a new glycoprotein IIb/IIIa platelet inhibitor DMP-444, labeled with technetium (Tc)

10             This protein, named the hookworm platelet inhibitor, has an estimated molecular mass of 1

11  suggesting a biologic role for the hookworm platelet inhibitor in vivo.

12                              Addition of the platelet inhibitor indomethacin to vitamin E simultaneou

13 ction platelet depletion or treatment with a platelet inhibitor is not protective.

14      One of the most important physiological platelet inhibitors is endothelium-derived prostacyclin

15 opose that a combination of antioxidants and platelet inhibitors might be rationally evaluated in the

16  collagen was substantially inhibited by the platelet inhibitors prostaglandin E1 and theophylline, t

17 potent, rapid-acting, reversible intravenous platelet inhibitor that was tested for percutaneous coro

18                                 Conventional platelet inhibitor therapy provides early but not persis

19  direct thrombin inhibitor (DTI) dabigatran; platelet inhibitors: thienopyridines (clopidogrel, ticlo

20                                      Several platelet inhibitors were examined in a tissue factor (TF